Sarcoma Clinical Trial
Official title:
A Pilot Study of Tumor Lysate-pulsed Dendritic Cell Vaccine for Immune Augmentation for High-risk Solid Tumor Patients Following Autologous Stem Cell Transplantation
Localized solid tumors such as, sarcoma, neuroblastoma, and Wilms' tumor, can generally be
effectively treated with a combination of surgery, radiation and chemotherapy. However,
patients with metastatic or relapsed disease have a very poor prognosis.
New approaches to the management of these difficult groups of patients are needed. There is
evidence to suggest that solid tumors may be good candidates for immunotherapy approaches. In
fact, recent experimental evidence indicates that the period of lymphopenia that occurs after
stem cell transplant may be an opportune time to use an immunotherapy treatment approach. In
light of the very poor prognosis of young patients with advanced solid tumors, this treatment
approach warrants further investigation.
Localized solid tumors such as, sarcoma, neuroblastoma, and Wilms' tumor, can generally be
effectively treated with a combination of surgery, radiation and chemotherapy. However,
patients with metastatic or relapsed disease have a very poor prognosis.
For the past decade, efforts to increase overall survival and progression-free survival for
patients with high-risk pediatric and young adult tumors, have evaluated the use of high-dose
chemotherapy and hematopoietic stem cell transplantation (HSCT). The proportion of patients
who enter a complete remission with HSCT is high, ranging from 81 to 90%. While autologous
HSCT renders a large proportion of patients temporarily disease-free, relapse develops in the
majority of patients.
Survival appears to have been most improved with this strategy for neuroblastoma, but
relapses occur in the majority of patients. Similar strategies have also been tried for
patients with advanced stage sarcoma and Wilms' tumor, but relapses are even more
problematic.
New approaches to the management of these difficult groups of patients are needed. There is
evidence to suggest that solid tumors may be good candidates for immunotherapy approaches. In
fact, recent experimental evidence indicates that the period of lymphopenia that occurs after
HSCT may be an opportune time to use this treatment approach. In light of the very poor
prognosis of young patients with advanced solid tumors, this treatment approach warrants
further investigation.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04457258 -
68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma
|
Early Phase 1 | |
Recruiting |
NCT04986748 -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
|
||
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Recruiting |
NCT04535713 -
GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
|
Phase 2 | |
Completed |
NCT03521531 -
Burden and Medical Care of Sarcoma in Germany
|
||
Completed |
NCT02496520 -
Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults
|
Phase 1/Phase 2 | |
Terminated |
NCT02054104 -
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
|
Phase 1/Phase 2 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT04577014 -
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
Completed |
NCT04052334 -
Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
|
Phase 1 | |
Completed |
NCT01593748 -
A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma
|
Phase 2 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Recruiting |
NCT04367779 -
Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
|
||
Completed |
NCT01879085 -
Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04553692 -
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers
|
Phase 1 | |
Completed |
NCT01209598 -
PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma
|
Phase 2 | |
Completed |
NCT04553471 -
Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers
|
N/A | |
Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 |